Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. IMAX
stocks logo

IMAX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
119.82M
+29.29%
0.469
+73.84%
91.85M
+5.98%
0.272
+109.57%
96.71M
+5.48%
0.294
+13.07%
Estimates Revision
The market is revising Upward the revenue expectations for IMAX Corporation (IMAX) for FY2025, with the revenue forecasts being adjusted by 0.22% over the past three months. During the same period, the stock price has changed by 21.66%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.22%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+8.22%
In Past 3 Month
Stock Price
Go Up
up Image
+21.66%
In Past 3 Month
Wall Street analysts forecast IMAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMAX is 37.60 USD with a low forecast of 32.00 USD and a high forecast of 42.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
Wall Street analysts forecast IMAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMAX is 37.60 USD with a low forecast of 32.00 USD and a high forecast of 42.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
3 Hold
0 Sell
Moderate Buy
Current: 36.230
sliders
Low
32.00
Averages
37.60
High
42.00
Current: 36.230
sliders
Low
32.00
Averages
37.60
High
42.00
Goldman Sachs
Sell -> Neutral
upgrade
$22 -> $34
2025-11-25
Reason
Goldman Sachs
Price Target
$22 -> $34
2025-11-25
upgrade
Sell -> Neutral
Reason
Goldman Sachs upgraded Imax to Neutral from Sell with a price target of $34, up from $22. The firm cites higher target multiples after including a takeover valuation methodology to reflect the growing strategic value of IMAX within the media industry for the upgrade. Goldman upgraded the shares ahead of the December 4 investor day.
JPMorgan
Neutral
maintain
$31 -> $32
2025-10-24
Reason
JPMorgan
Price Target
$31 -> $32
2025-10-24
maintain
Neutral
Reason
JPMorgan raised the firm's price target on Imax to $32 from $31 and keeps a Neutral rating on the shares.
Roth Capital
Buy
maintain
$36 -> $40
2025-10-14
Reason
Roth Capital
Price Target
$36 -> $40
2025-10-14
maintain
Buy
Reason
Roth Capital raised the firm's price target on Imax to $40 from $36 and keeps a Buy rating on the shares. The company's strategic initiatives have helped drive record Q3 global box office results and its second-highest quarterly gross ever, while its market share continues to rise and local language titles have served as a source of strength, the analyst tells investors in a research note. Imax network expansion is occurring at a faster-than-projected pace and is taking place for the most part in markets with above-average revenue per screen, the firm added.
Barrington
Outperform
maintain
$32 -> $37
2025-09-19
Reason
Barrington
Price Target
$32 -> $37
2025-09-19
maintain
Outperform
Reason
Barrington raised the firm's price target on Imax to $37 from $32 and keeps an Outperform rating on the shares following meetings with management. The firm cites its outlook for continued box office growth for the target increase. The demand for a premium experience has supported the increased box office share for Imax, the analyst tells investors in a research note. Barrington believes expanded content offerings can benefit the company over the long term.
Rosenblatt
Rosenblatt
Buy
maintain
$35 -> $37
2025-07-25
Reason
Rosenblatt
Rosenblatt
Price Target
$35 -> $37
2025-07-25
maintain
Buy
Reason
Rosenblatt raised the firm's price target on Imax to $37 from $35 and keeps a Buy rating on the shares. The firm is "pounding the table" on the shares after the company reported another quarter of upside. The shares are not pricing in Imax's growing market share, the strength of the film slate over the next few years and the potential for additional margin expansion as the box office grows.
Seaport Research
David Joyce
maintain
$31 -> $38
2025-07-25
Reason
Seaport Research
David Joyce
Price Target
$31 -> $38
2025-07-25
maintain
Reason
Seaport Research analyst David Joyce raised the firm's price target on Imax to $38 from $31 and keeps a Buy rating on the shares. The firm raised its price target on the stick given margin and multiple expansion heading into FY26, the analyst tells investors.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Imax Corp (IMAX.N) is 24.51, compared to its 5-year average forward P/E of 33.49. For a more detailed relative valuation and DCF analysis to assess Imax Corp 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
33.49
Current PE
24.51
Overvalued PE
81.44
Undervalued PE
-14.46

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
12.27
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
18.22
Undervalued EV/EBITDA
6.31

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
3.19
Current PS
0.00
Overvalued PS
4.02
Undervalued PS
2.36
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 585.13% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 585.13% over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

IMAX News & Events

Events Timeline

(ET)
2025-12-04
15:00:00
IMAX Sets Three-Year Financial Targets: Revenue Growth in Low Double Digits
select
2025-11-03 (ET)
2025-11-03
06:50:37
Imax Plans to Issue $220 Million in Convertible Senior Notes Maturing in 2030
select
2025-10-27 (ET)
2025-10-27
08:42:46
Imax and Cinemark Reach Deal for Imax with Laser Technology
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
5.0
12-02Benzinga
"Zootopia 2 Sets Box Office Records: Could Disney Stock Gain From This Success?"

  • Zootopia 2's Box Office Success: "Zootopia 2" emerged as the top-grossing film over the Thanksgiving weekend, earning $156 million domestically and $556 million globally, setting multiple box office records, including the second-largest non-local opening in China.

  • Impact on Disney's Financial Outlook: The film's strong performance, particularly in China, could positively influence Disney's stock and overall financial health as it heads into 2025, despite the company's stock being down 5% year-to-date.

  • IMAX Performance: The film contributed significantly to IMAX's record Thanksgiving weekend, generating $32 million in IMAX ticket sales, marking the biggest Thanksgiving title ever for the company.

  • Future Releases and Expectations: Following "Zootopia 2," Disney anticipates further success with upcoming releases, including "Avatar: Fire and Ash," and has a promising lineup for 2026, which includes major titles like "Mandalorian and Grogu" and "Avengers: Doomsday."

[object Object]
Preview
7.5
12-01Newsfilter
Eli Lilly Cuts Zepbound Prices to $299 on Direct-to-Consumer Platform
  • Price Adjustment: Eli Lilly announced a reduction in the cash price of its weight-loss drug Zepbound to between $299 and $449 per single-dose vial, down from the previous range of $349 to $499, aiming to enhance drug accessibility in line with government initiatives for price transparency.
  • Market Response: This pricing strategy follows agreements made by President Trump with Eli Lilly and its competitor Novo Nordisk, which is expected to attract more patients to the drug, thereby increasing the company's market share and competitiveness in the weight-loss drug sector.
  • Industry Impact: As competition intensifies in the weight-loss drug market, Lilly's price cut may prompt other pharmaceutical companies to adopt similar strategies, potentially leading to a price war that could affect profit margins across the industry.
  • Consumer Benefits: By lowering drug prices, Eli Lilly not only meets the demand for affordable medications but also enhances its brand image and strengthens consumer loyalty, which could further drive sales growth.
[object Object]
Preview
4.5
12-01CNBC
Eli Lilly Reduces Prices, Thanksgiving Box Office Update, Challenges for Gravestone Manufacturers, and More in Morning Squawk

  • Market Performance: The Dow Jones Industrial Average and S&P 500 both completed their seventh consecutive winning month, although technology stocks faced challenges due to concerns over artificial intelligence spending.

  • Eli Lilly Price Cuts: Eli Lilly announced a reduction in the cash price of its weight-loss drug Zepbound, now available for $299 to $449 per month, following recent agreements to enhance drug accessibility.

  • Thanksgiving Box Office Success: The Thanksgiving weekend box office is projected to be one of the best ever, with an estimated $294 million in sales, led by Disney's "Zootopia 2," which grossed around $156 million.

  • Airbus Quality Issues: European shares of Airbus fell due to reports of a quality issue affecting A320-family aircraft, leading to delayed deliveries, although no current planes in service are impacted.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Imax Corp (IMAX) stock price today?

The current price of IMAX is 36.23 USD — it has increased 8.44 % in the last trading day.

arrow icon

What is Imax Corp (IMAX)'s business?

Imax Corporation is a premier global technology platform for entertainment and events. Through its proprietary software, auditorium, architecture, patented intellectual property, and specialized equipment, the Company offers an end-to-end solution to create content experiences. The Company operates through two segments: Content Solutions and Technology Products and Services. The Content Solutions segment principally includes content enhancement and distribution services. This segment is also engaged in the distribution of large-format documentary films and exclusive experiences ranging from live performances to interactive events with artists and creators, as well as film post-production services. The Technology Products and Services principally include the sale, lease, and maintenance of IMAX Systems. This segment is also involved in ancillary theater business activities, including after-market sales of IMAX System parts and three-dimensional (3D) glasses.

arrow icon

What is the price predicton of IMAX Stock?

Wall Street analysts forecast IMAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMAX is 37.60 USD with a low forecast of 32.00 USD and a high forecast of 42.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Imax Corp (IMAX)'s revenue for the last quarter?

Imax Corp revenue for the last quarter amounts to 106.65M USD, increased 16.62 % YoY.

arrow icon

What is Imax Corp (IMAX)'s earnings per share (EPS) for the last quarter?

Imax Corp. EPS for the last quarter amounts to 0.37 USD, increased 42.31 % YoY.

arrow icon

What changes have occurred in the market's expectations for Imax Corp (IMAX)'s fundamentals?

The market is revising Upward the revenue expectations for IMAX Corporation (IMAX) for FY2025, with the revenue forecasts being adjusted by 0.22% over the past three months. During the same period, the stock price has changed by 21.66%.
arrow icon

How many employees does Imax Corp (IMAX). have?

Imax Corp (IMAX) has 700 emplpoyees as of December 05 2025.

arrow icon

What is Imax Corp (IMAX) market cap?

Today IMAX has the market capitalization of 1.95B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free